Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Arcturus Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, risk, profitability, earnings and valuation.
Risk & Volatility
Arcturus Therapeutics has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares Arcturus Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Arcturus Therapeutics | $82.03 million | -$65.78 million | -2.71 |
| Arcturus Therapeutics Competitors | $693.35 million | $8.05 million | -18.80 |
Arcturus Therapeutics’ rivals have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Arcturus Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcturus Therapeutics | 1 | 0 | 6 | 2 | 3.00 |
| Arcturus Therapeutics Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
Arcturus Therapeutics presently has a consensus target price of $24.50, indicating a potential upside of 193.06%. As a group, “Biotechnology” companies have a potential upside of 126.22%. Given Arcturus Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than its rivals.
Profitability
This table compares Arcturus Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcturus Therapeutics | -285.92% | -46.79% | -36.50% |
| Arcturus Therapeutics Competitors | -12,224.09% | -202.33% | -31.23% |
Summary
Arcturus Therapeutics beats its rivals on 9 of the 12 factors compared.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
